Previous 10 | Next 10 |
YAVNE, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a peer-reviewed paper, titled “ An Open-label, Proof of Concept Study, Assessing the Effects of...
2023-12-18 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-21 13:14:09 ET MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript November 21, 2023 08:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corp...
2023-11-21 07:05:36 ET More on MediWound 3M to join MediWound in Phase 3 trial for wound care product MediWound burn therapy NexoBrid launched in US Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWound Financial info...
NexoBrid ® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx ® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Cash of $46 million; Opera...
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and ...
Freightos Limited (CRGO) is expected to report $-0.14 for Q3 2023 Magyar Telekom Telecommunications ADR (MYTAY) is expected to report for Q3 2023 IMAC Holdings Inc. (BACK) is expected to report for Q1 2024 NewJersey Resources Corporation (NJR) is expected to report $0.3 for Q4 2023 ...
MediWound Ltd. (MDWD) is expected to report $-0.45 for Q3 2023
2023-11-20 12:56:52 ET More on MediWound 3M to join MediWound in Phase 3 trial for wound care product MediWound burn therapy NexoBrid launched in US Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWound Financial info...
YAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 on Tuesday, November 21...
News, Short Squeeze, Breakout and More Instantly...
MediWound Ltd. Company Name:
MDWD Stock Symbol:
NASDAQ Market:
Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase II...
Shares of MediWound Ltd. (NASDAQ: MDWD) traded at a new 52-week high today and are currently trading at $17.39. So far today, approximately 35,312 shares have been exchanged, as compared to an average 30-day volume of 101.83k shares. MediWound Ltd., a biopharmaceutical company, develops, manu...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...